INVESTORS
Stock Information
State of Linical’s Stock
AS OF MARCH 31, 2024
TOTAL NO. OF AUTHORIZED SHARES
49,600,000
TOTAL NO. OF ISSUED SHARES
24,740,000
NO. OF SHAREHOLDERS
5,520
Major Shareholders
AS OF MARCH 31, 2024
NAME
NO. OF SHARES
PROPORTION OF SHARES (%)
HATANO CO. LTD.
4,500 K
19.93
TAKAHASHI CO. LTD.
1,994
8.83
KEIGO TSUJIMOTO
1,024
4.53
SAKAMOTO CO. LTD.
810
3.58
KAZUHIRO HATANO
742
3.28
AKIHIRO TAKAHASHI
741
3.28
ISAO SAKAMOTO
735
3.25
KOICHI TAKAGI
720
3.18
JUN KAWAI
600
2.65
MASAYA MIYAZAKI
600
2.65
NOTE: Linical owns 2,153,564 shares in its own stock, separate to the shareholdings outlined above.
Shareholdings by Shareholder
% OF SHARES AS OF MARCH 31, 2024
8.70%
Treasury Shares
(1 person)
2,153 Thousands of shares
1.33%
Foreign Companies
(61 people)
328 Thousands of shares
31.96%
Other Domestic Companies
(26 people)
7,905 Thousands of shares
1.82%
Securities Firms
(30 people)
449 Thousands of shares
51.26%
Individuals & Others
(5,393 people)
12,681 Thousands of shares
4.93%
Financial Instiutions
(9 people)
1,221 Thousands of shares
Want to learn more? Contact the Linical Investor Relations Team.
Successful clinical trials start with Linical.
Don’t let the complex clinical development journey hold you back. With Linical, you can overcome obstacles, save valuable time and money, and reach your goals.
01 Request a proposal
We start by listening to your needs and understanding your goals to ensure we’re the right CRO for you.
02 Get a plan for success
We propose solutions that proactively tackle obstacles, optimize your trial design, and position you for success every step of the way.
03 Execute with confidence
We’ll guide you through each phase of the process, offering personalized support and a full range of services to help you achieve a successful trial. We are not a “one size fits all” CRO.